AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change
26-07-16	€0.6400	0.00%
26-07-15	€0.6400	-7.38%
26-07-14	€0.6910	-4.16%
26-07-13	€0.7210	-2.70%
26-07-10	€0.7410	+0.14%

Delayed Quote Deutsche Boerse AG

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Tradegate Other stock markets 15:12:08 2026-07-16 EDT			5-day change	1st Jan Change
0.6160 ^EUR	-3.75%		-13.51%	-53.08%

07-01	AB Science, successful private placement
06-30	AB Science S.A. announced that it has received ?2.294 million in funding	CI

Market Cap	49.45M 56.57M 45.73M 41.96M 79.42M 5.45B 80.8M 545M 214M 2.66B 212M 208M 9.19B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	49.45M 56.57M 45.73M 41.96M 79.42M 5.45B 80.8M 545M 214M 2.66B 212M 208M 9.19B	EV / Sales 2026 *	41.2x	EV / Sales 2027 *	38x
Free-Float	63.24%	Yield 2026 *	-	Yield 2027 *	-

07-01	AB Science, successful private placement
06-30	AB Science S.A. announced that it has received ?2.294 million in funding	CI
06-29	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI
06-29	AB Science completes Step 3 of a Phase 1 study
06-18	AB Science Secures US Patent for Prostate Cancer Therapy	MT
06-18	AB Science Secures New U.S. Patent for Masitinib
06-17	AB Science Patent For Masitinib In The Treatment Of Metastatic Castrate Resistant Prostate Cancer Formally Granted In The United States With Protection Until 2042	CI
06-10	AB Science presents new data on Masitinib
05-17	AB Science S.A. announced that it has received $2.989368 million in funding	CI
05-13	AB Science S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-03	AB Science S.A. announced that it expects to receive $2.989368 million in funding	CI
04-29	Airbus, Pernod Ricard, Sopra Steria, TotalEnergies, TP... stocks to watch today in Paris
04-29	AB Science announces successful capital increase

07-10	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs	GL
07-08	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU
07-01	AB Science announces the successful completion of a EUR 2.3 million private placement	GL
06-29	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	GL
06-29	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	AQ

AB Science Stock Deutsche Boerse AG

Stocks

A8D

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Course Extremes

Managers and Directors: AB Science

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

07-13	Bourse : Go West pour Stellantis, Apple se fâche contre OpenAI, Akzo courtisé
07-13	Wall Street ne chômera pas le 14 juillet
07-10	AB Science rationalise son portefeuille et se recentre sur deux molécules
07-10	AB Science fait le point sur son programme clinique avec l’arrêt de certaines études cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques
07-08	Stéphane Ledermann prend les rênes d'AB Science en tant que PDG

1 day	-3.75%
1 week	-13.51%
Current month	-28.33%
1 month	-27.60%
3 months	-47.54%
6 months	-54.42%
Current year	-53.08%

1 week	0.64	0.74
1 month	0.64	0.99
Current year	0.64	1.55
1 year	0.64	1.6
3 years	0.64	4.07
5 years	0.64	15.72
10 years	0.64	20.1

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	2026-07-06
Laurent Guy DFI	Director of Finance/CFO	-	2009-11-19
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	2018-03-31

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	2001-07-10
Patrick Moussy BRD	Director/Board Member	-	2011-09-19
Cécile de Guillebon BRD	Director/Board Member	64	2021-06-26

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-3.75%	-13.51%	-	-	59.03M
MERCK & CO., INC.	+3.45%	+2.45%	+55.45%	+21.38%	305B
MERCK KGAA	-1.53%	-1.18%	+24.90%	-7.29%	69.67B
HALOZYME THERAPEUTICS, INC.	+2.20%	-1.25%	+33.84%	+92.80%	8.99B
KYOWA KIRIN CO., LTD.	+0.23%	-1.27%	+6.72%	-0.25%	8.52B
BETTA PHARMACEUTICALS CO., LTD.	-3.05%	+4.98%	+10.85%	+28.13%	4.17B
SK BIOPHARMACEUTICALS CO., LTD.	+1.53%	-3.29%	-19.72%	+3.79%	4.11B
YUHAN CORPORATION	+1.87%	+2.46%	-37.23%	+24.94%	3.48B
SUPERNUS PHARMACEUTICALS, INC.	+0.26%	-1.62%	+43.08%	+62.96%	2.77B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-0.81%	+8.11%	+14.84%	-16.29%	2.28B
Average	+0.03%	-1.83%	+14.75%	+23.35%	45.48B
Weighted average by Cap.	+2.37%	-4.79%	+46.45%	+17.61%

	2026 *	2027 *
Net sales	1.2M 1.37M 1.11M 1.02M 1.93M 132M 1.96M 13.23M 5.2M 64.6M 5.16M 5.04M 223M	1.3M 1.49M 1.2M 1.1M 2.09M 143M 2.12M 14.34M 5.63M 69.98M 5.59M 5.46M 242M
Net income	-	-
Net Debt	-	-